Decadal analysis of deceased organ donation in Spain and the United States linking an increased donation rate and the utilization of older donors

Jeff Halldorson, John Paul Roberts – 19 June 2013 – After the foundation of the National Transplant Organization, Spanish rates of deceased donor donation rapidly outpaced US growth over the decade from 1989 to 1999. An analysis of the following decade, 1999‐2009, demonstrated a markedly flattened growth curve for Spanish deceased donor organ procurement, which increased only 2.4% from 33.6 to 34.4 donors per million population (pmp). In comparison, over the same decade in the United States, the rate of deceased donation increased from 20.9 to 26.3 donors pmp (25.8%).

Long‐term deleterious effects of aortohepatic conduits in primary liver transplantation: Proceed with caution

Taizo Hibi, Seigo Nishida, David M. Levi, Daisuke Sugiyama, Kyota Fukazawa, Akin Tekin, Ji Fan, Gennaro Selvaggi, Phillip Ruiz, Andreas G. Tzakis – 19 June 2013 – Aortohepatic conduits provide a vital alternative for graft arterialization during liver transplantation. Conflicting results exist with respect to the rates of comorbidities, and long‐term survival data on primary grafts are lacking.

Preformed class II donor‐specific antibodies are associated with an increased risk of early rejection after liver transplantation

Jacqueline G. O'Leary, Hugo Kaneku, Linda W. Jennings, Nubia Bañuelos, Brian M. Susskind, Paul I. Terasaki, Göran B. Klintmalm – 18 June 2013 – Preformed donor‐specific human leukocyte antigen antibodies (DSAs) are considered a contraindication to the transplantation of most solid organs other than the liver. Conflicting data currently exist on the importance of preformed DSAs in rejection and patient survival after liver transplantation (LT).

Quality of life is significantly impaired in long‐term survivors of acute liver failure and particularly in acetaminophen‐overdose patients

Amol S. Rangnekar, Caitlyn Ellerbe, Valerie Durkalski, Brendan McGuire, William M. Lee, Robert J. Fontana – 18 June 2013 – Functional outcomes for long‐term survivors of acute liver failure (ALF) are not well characterized. The aim of this prospective study was to determine health‐related quality of life in long‐term adult ALF survivors. Acute Liver Failure Study Group registry participants completed the Centers for Disease Control and Prevention Health‐Related Quality of Life 14 and Short Form 36 (SF‐36) questionnaires at 1‐ and/or 2‐year follow‐up study visits.

Improved Waiting‐List Outcomes in Argentina After the Adoption of a Model for End‐Stage Liver Disease–Based Liver Allocation Policy

Nora Gabriela Cejas, Federico G. Villamil, Javier C. Lendoire, Viviana Tagliafichi, Arturo Lopez, Daniela Hansen Krogh, Carlos A. Soratti, Liliana Bisigniano – 15 June 2013 – In July 2005, Argentina became the first country after the United States to introduce the Model for End‐Stage Liver Disease (MELD) for organ allocation. In this study, we investigated waiting‐list (WL) outcomes (n = 3272) and post–liver transplantation (LT) survival in 2 consecutive periods of 5 years before and after the implementation of a MELD‐based allocation policy.

Calcineurin Inhibitor–Free Mycophenolate Mofetil/Sirolimus Maintenance in Liver Transplantation: The Randomized Spare‐the‐Nephron Trial

Lewis Teperman, Dilip Moonka, Anthony Sebastian, Linda Sher, Paul Marotta, Christopher Marsh, Baburao Koneru, John Goss, Dennis Preston, John P. Roberts, Spare‐the‐Nephron Trial Liver Transplantation Study Group – 15 June 2013 – Mycophenolate mofetil (MMF) and sirolimus (SRL) have been used for calcineurin inhibitor (CNI) minimization to reduce nephrotoxicity following liver transplantation.

Population‐based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis

Kirsten Boonstra, Rinse K. Weersma, Karel J. Erpecum, Erik A. Rauws, B.W. Marcel Spanier, Alexander C. Poen, Karin M. Nieuwkerk, Joost P. Drenth, Ben J. Witteman, Hans A. Tuynman, Anton H. Naber, Paul J. Kingma, Henk R. Buuren, Bart Hoek, Frank P. Vleggaar, Nan Geloven, Ulrich Beuers, Cyriel Y. Ponsioen, on behalf of the EpiPSCPBC Study Group – 14 June 2013 – Extensive population‐based studies are much needed to accurately establish epidemiology and disease course in patients with primary sclerosing cholangitis (PSC).

Subscribe to